BioInformatics, an Arlington, VA-based strategic services company for the life science, clinical diagnostics, analytical instrumentation, radiology, and dental markets, raised $21m in Series B funding.
Backers included BroadOak Capital, Pablo Capital and Research Corporation Technologies.
The company intends to use the funds for the Kalorama acquisition and other growth initiatives with additional capital reserved to fund future strategic acquisitions. As a result of the financing, Mark Anderson, a Partner with Pablo Capital, will join the BioInformatics Board of Directors, along with existing board members Bill Snider and Tim Johnson of BroadOak Capital.
BioInformatics, now part of Science and Medicine Group, a a research and advisory firm serving the life science, clinical diagnostics and analytical instrument industries. By leveraging an expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to improved business decisions.
The Science and Medicine Group is a platform to support the dynamic changes in the marketplace as science and medicine converges to measure and detect changes in the body and the environment. Over 500 companies in the life science, clinical diagnostics, radiology, and dental markets have launched products on the company’s digital platforms or used its market intelligence data and publications.
The assets of Kalorama Information will be combined with existing capabilities including BioInfo Market Research, The Science Advisory Board, Strategic Directions International (SDi) creator of the SDi Global Assessment Report, Instrument Business Outlook a bi-weekly publication subscribed to and read by senior executives in the analytical instrument market, and IMV, a leader in the radiology and diagnostics space. Together, all companies and assets will be managed and integrated under the Science and Medicine Group.